Kornimate/medical-research-clean huggingface dataset:
64 cu-dota-alendronate pet imaging in localizing and characterizing breast calcifications in participants before undergoing mastectomy

Conditions: Breast Carcinoma; Calcification

Summary: this early phase i pilot trial studies how well 64cu-dota-alendronate positron emission tomography (pet) imaging work in localizing and characterizing breast calcifications (small calcium deposits) in participants before undergoing mastectomy. diagnostic procedures, such 64cu-dota-alendronate pet, may detect calcification and help doctors predict cancer associated calcification within breast tissue.

primary objectives: i. to evaluate the uptake (maximum standardized uptake value \[suvmax\]) of 64cu-dota-alendronate in female patients with biopsy-proven malignant breast calcifications. secondary objectives: i. to compare uptake of 64cu-dota-alendronate on pet -computed tomography (ct) with histology after mastectomy. outline: this is a dose-escalation study of 64cu-dota-alendronate. participants receive 64cu-dota-alendronate intravenously (iv) and undergo pet/ct imaging 60 minutes after injection. participants with sufficient levels of residual radioactivity may undergo repeat imaging on day 1 as determined by the study team. after completion of study , participants are followed up for 7 days.

Eligibility criteria:
inclusion criteria: * evidence of calcifications on mammogram * biopsy confirmed malignancy associated calcifications in at least one breast * biopsy confirmed benign calcifications in at least one breast (same or contralateral breast) * planned total mastectomy for treatment * ability to provide informed consent * negative serum pregnancy test * no evidence of impaired hepatic or kidney function exclusion criteria: * participants who do not have residual calcifications present on mammogram following biopsy * concurrent malignancy other than non-melanoma skin cancer * patients with known metastatic disease * patients who have received prior treatment for the current breast cancer * patients currently using oral bisphosphonate therapy * patients with injection of other radioactive material within 90 days * inability to provide informed consent * pregnant or lactating patients * patients with impaired kidney function (creatinine \>= 1.3 mg/dl or \< 0.6 mg/dl)
perceptions, experiences, and activity in cancer survivors during covid-19

Conditions: Neoplasms Malignant

Summary: to examine perceptions and determinants of physical activity during the covid-19 pandemic among cancer survivors.

this purpose of this study is to examine perceptions and determinants of physical activity during the covid-19 pandemic in cancer survivors. to test our aim, we will recruit up to 1000 adults diagnosed with cancer within the last five years and ask them to complete an online questionnaire battery assessing their self-reported physical activity habits, psychosocial outcomes (e.g., depression, anxiety, self-efficacy, social support), and perceptions of physical activity engagement during the pandemic. a subsample of participants (n=50) will also be invited to participate in an interview to gain further insights into cancer survivors' physical activity experiences during covid-19. analysis of covariance (ancova) will be used to analyze the quantitative survey data, and thematic analysis will be used to analyze the qualitative interview data.

Eligibility criteria:
inclusion criteria: * adult with a history of cancer (except non-invasive skin cancer) * diagnosed at age 19 or older * diagnosed within 5 years of study enrollment * access to a computer, tablet, or smartphone with the internet * english reading exclusion criteria: * unable to read in english

Keywords: physical activity covid cancer
genetic abnormalities and oxidative stress in sperm as cause of recurrent miscarriage.

Conditions: Recurrent Miscarriage

Summary: in recurrent miscarriage, the male factor has been poorly evaluated. in fact, in the vast majority of clinical protocols of recurrent miscarriage, the sperm is not considered or assessed. recently, some studies have suggested the presence of genetic and metabolic sperm anomalies in couples suffering from repeated miscarriages. specifically, dna fragmentation and altered oxidative stress in the sperm and y microdeletions from blood samples have been related to an increased risk of miscarriage.the aim of the present study is to compare these three parameters in: couples with recurrent miscarriage; oligozoospermic men with or without recurrent miscarriages; and healthy sperm donors, in order to determine their actual impact on this reproductive problem.


Eligibility criteria:
inclusion criteria: 4 groups * recurrent miscarriage, \<40 year-old-men, \< 38 year-old-women, normal or mild affected sperm, normal parents karyotype, no thrombophilia, normal uterus, no endocrinopathy * the same criteria than in group a, but oligozoospermia (1-5 mill/ml) * oligozoospermia (1-5 mill/ml), \< 40 year-old-men, no recurrent miscarriages * healthy young sperm donors
differential risks for melanoma: p16 and dna repair

Conditions: Melanoma; Skin Melanoma

Summary: the goal of this study is to find out if some people are more likely to get melanoma, a form of skin cancer, than others. people respond to the environment in different ways. some may be born with genes that make them more likely to get this type of skin cancer. genes are made up of dna. dna damage is one of the first steps in developing cancer. each person has many ways to repair normal damage to their genes. some people may have a lower level of this repair and that may make them more likely to get cancer. some genes are important for dna repair. the genes we want to test are thought to affect the rate at which dna can be repaired. we also want to find out if sun habits are related to these levels of dna repair or genetic mutations.


Eligibility criteria:
inclusion criteria: * cases will be patients 18 years or older with a histologically confirmed, second or multiple primary melanoma. these will be sequentially selected from subjects seen at memorial sloan-kettering cancer center or the yale university pigmented lesion clinic. * controls will be patients 18 years or older with a histologically confirmed first primary melanoma diagnosed no earlier than 12 months prior to the study start date. one control will be selected per case. these patients will be referred to the study by the melanoma disease management team at memorial sloan-kettering cancer center. controls will be frequency-matched to cases on the basis of sex and age (within 10 year age groups). * healthy controls will be subjects 18 years or older recruited from the general population through random digit dialing. these subjects will have no history of melanoma. they will also be frequency matched to cases on the basis of sex and 10-year age group. * the subject must have a histologically confirmed malignant melanoma. * cases may have an in situ melanoma as the second primary. * melanoma controls may have only one primary melanoma. * healthy controls should have no history of melanoma. * the subject's physician consents to his/her patient's participation in the study (if the subject has a diagnosis of melanoma). * the subject has consented, in writing, to participate in the study exclusion criteria: * karnofsky status less than 60 (see appendix). this will be evaluated by the physician treating the subject for melanoma at the time permission is given for participation * patient had chemotherapy or radiation therapy within the last 6 weeks.
effects of perturbation therapy and trunk control training

Conditions: Cerebral Palsy

Summary: a postural perturbation refers to unexpected change in conditions that upsets the body's harmony and displaces its posture. these perturbations can be sensory in nature, such as vestibular perturbations resulting from electrical stimulation, visual perturbations caused by a moving room or graphical images, or somatosensory perturbations caused by muscle vibrations. the body's reactions to these sensory perturbations may be based on the perception of instability rather than actual imbalance. trunk control plays a vital role in various aspects of daily life, including balance, walking, and overall functional abilities. children with cerebral palsy (cp), who experience limitations in their ability to move, often expend more energy compared to their healthy peers.

this study will be randomized clinical trial used to compare the effects of perturbation and trunk control training in children with cerebral palsy. subjects meeting the predetermined inclusion and exclusion criteria will be divided into two groups using lottery method. pre-assessment will be done using berg balance scale, functional independent measures and tug test as objective measurements. subjects in one group will be treated using perturbation therapy and the other one will be treated with trunk control training. both groups had three treatment sessions per week, for 4 weeks, and the total time for every session was about 30-45 minutes. a postural perturbation refers to unexpected change in conditions that upsets the body's harmony and displaces its posture. these perturbations can be sensory in nature, such as vestibular perturbations resulting from electrical stimulation, visual perturbations caused by a moving room or graphical images, or somatosensory perturbations caused by muscle vibrations. the body's reactions to these sensory perturbations may be based on the perception of instability rather than actual imbalance. on the other hand, "mechanical perturbations" physically displace the body segments, potentially leading to a shift in the overall center of mass or actual imbalance. even small displacements of a single body segment, like the head, can elicit minor muscle responses throughout the body

Eligibility criteria:
inclusion criteria: * kids that suffer from cerebral palsy. * ages span from 5 to 10 years. * both males and females were represented. * during the preceding half-year, there was no orthopedic surgery or spasticity-reduction intervention. * no significant lower limb muscular contraction exclusion criteria: * individuals suffering from sensory, proprioceptive, cognitive, and perceptual impairments, as well as those with contractures. * any neurological disease that impairs balance, including orthopedic disorders * individual experiencing seizures and has undergone any prior surgical treatments. * uncorrected visual issues

Keywords: cerebral palsy perturbation therapy trunk control training.
coats plus syndrome and lcc syndrome: series of 10 pediatric cases. review of literature and natural history

Conditions: Coats Disease

Summary: coats plus syndrome is a very rare and serious disease, caused by premature telomere shortening. it is a pediatric, multi-systemic disease, the main features of which are retinal vasculopathy and neurological disorders, associated with brain calcification and leukodystrophy. its precise genetic etiology was discovered in 2012: autosomal recessive mutation of the ctc1 gene. publications about this syndrome are very few, and consist only of case reports, or small series of cases. this is explained by the rarity of occurrence of this syndrome. since 1988, 57 cases of coats plus syndrome have been published, with case series of up to 13 patients. only 28 cases were detailed concerning the precise clinical presentation in the literature. the general characteristics of this syndrome are known and, in addition to the ophthalmological and neurological damage, the various publications have been able to report a digestive attack (hemorrhages), hematological damage (central cytopenias), or increased bone fragility. no treatment is currently available to cure patients. the natural history of this disease is poorly known. however, the most accurate knowledge possible of this disease, and its natural history, is essential. it would allow an easier identification of this rare syndrome, the establishment of a management (monitoring and therapeutic) adapted, and a more accurate genetic counseling in case of need of a prenatal diagnosis. the description of a new series of unpublished cases, as well as a comprehensive review of the literature on coats plus syndrome, will provide a more comprehensive and informed view of this disease. moreover, lcc syndrome (leukoencephalopathy with calcifications and cysts) is an autosomal recessive disorder linked to a mutation in the snord118 gene, which has the particularity of presenting the same neurological (neuro-radiological and clinical) characteristics, but without associating the others. ophthalmological and systemic disorders. it constitutes the differential radiological diagnosis of coats plus syndrome. in this, the collection of medical data of french pediatric cases presenting this syndrome will allow a more detailed analysis of the differences and similarities between these two syndromes.


Eligibility criteria:
inclusion criteria: * patient with coats plus genetic and / or clinical syndrome, pediatric onset * patients with genetic and / or clinical lcc syndrome, pediatric onset exclusion criteria: * refusal of the patient or his family (oral opposition)

Keywords: coats leukencephalopathy with calcifications and cysts
a platform of patient derived xenografts (pdx) and 2d/3d cell cultures of soft tissue sarcomas (sts)

Conditions: Soft Tissue Sarcoma; Xenograft Model; 2D/3D Cell Cultures

Summary: outside the setting of well-designed prospective clinical studies, the current standard preoperative rt should be a conventionally 1.8-2 gy fractionated regimen to a total dose of 50 gy in 5-6 weeks. however, given the vast diversity of sarcoma subtypes, it is also unlikely to assume a uniform therapeutic management to be optimal for all sarcomas alike. other than 2 gy fraction sizes and/or 50 gy total dose series have been investigated in the past and should be further exploited in the future, but the practical implementation in humans is hampered by the rarity of the disease. the current systemic treatment of sarcomas consists of both the older cytotoxic chemotherapies and the newer targeted therapies like tyrosine kinase inhibitors. but it is hard to predict which patients will respond to which specific systemic treatment. this leads to worse prognoses and unnecessary toxicity for sarcoma patients. despite the fact that the number of sarcoma patients in current studies is too small with a mix of different subtypes, some subtypes show a better response than other subtypes. this platform may form the basis for preclinical translational investigations with radiotherapy and various systemic treatments.


Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosed (non-) metastatic intermediate to high grade sts * local recurrences are allowed * age ≥ 18 years * able and willing to undergo tumour biopsies or tumour sampling during surgery * localization of sarcoma enables safe biopsy or surgery * written informed consent exclusion criteria: * known coagulation disorder and/or anticoagulant medication in as far it might interfere with a safe biopsy procedure (to the discretion of the treating physician and attending radiologist) * any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the study
description of case of infection with a new species of babesia and its molecular diagnosis

Conditions: Babesiosis, Human

Summary: babesiosis is a potentially very serious infection, but too little known. investigators want to raise their clinical colleagues and remind fellow biologists of the importance of choosing a good molecular diagnosis so as not to give false-negative results.


Eligibility criteria:
inclusion criteria: * major subject (≥18 years old) * splenectomized subject * subject with severe babesiosis * subject not having expressed, after information, his opposition to the reuse of his data for the purposes of this research exclusion criteria: - subject having expressed opposition to participating in the study

Keywords: babesiosis babesia zoonoses
immobilization versus observation in children with toddler's fractures: a prospective randomized controlled trial

Conditions: Tibial Fractures

Summary: toddler's fractures of the tibia are by definition non-displaced and of a stable pattern. children have thickened periosteum compared with adults, which therefore may impart stability to the fracture without the need for additional immobilization. the goal of the study is to evaluate whether or not there is a difference in children treated with and without cast immobilization in regards to time to ambulation; perceived pain; difficulty in dressing \& bathing; radiographic displacement or angulation; and time missed from work or daycare. our null hypothesis is that there will be no difference in clinical or radiographic outcomes between the groups.


Eligibility criteria:
inclusion criteria: * • children ages 1-5 years old with radiographic evidence of a non-displaced spiral or oblique fracture of the tibial shaft or metaphysis. exclusion criteria: * • children with clinical suspicion but lack of radiographic evidence for toddler's fracture * fractures displaced \>2mm * open fractures * pathologic fracture * fractures involving the physis * previous fracture of the ipsilateral extremity * concomitant fracture involving the ipsilateral or contralateral leg * concomitant head injury * non-ambulatory children (i.e., those who have not yet begun to walk) * children with bone-metabolism disorders (i.e., osteogenesis imperfect, rickets) * children who are geographically prohibited from following up in our system * children whose caregivers are not proficient in english * presentation \>7 days from injury * cases considered to be non-accidental trauma

Keywords: toddler's fracture tibial fracture children
energy expenditure in patients with ulcerative colitis undergoing surgery

Conditions: Ulcerative Colitis; Surgery

Summary: a prospective observational study to assess the energy needs of ulcerative colitis patients undergoing total proctocolectomy with ileoanal j-pouch anastomosis.

total proctocolectomy with creation of ileoanal j-pouch anastomosis is the gold-standard surgical procedure for familial polyposis, for ulcerative colitis unresponsive to medication and for colitis associated with dysplasia requiring total colectomy. patients postoperatively face difficulties in maintaining their physical condition and quality of life due to potential complications such as surgical, mechanical, inflammatory and functional disorders increasing the rates of malnutrition. postoperative changes as regards anthropometric characteristics and nutritional status have not been fully elucidated. therefore, the need arises to calculate the energy needs of patients with ileoanal j-pouch anastomosis, given the lack of corresponding data and the possible differentiation of energy needs from a similar group of patients undergoing colorectal surgery. of particular interest is the body composition of ileoanal anastomosis patients, which has been studied very little ), and the extent to which their energy needs are met, given dietary restrictions both preoperatively and postoperatively. it is therefore necessary to determine the energy needs, as well as the degree of their coverage by the diet, of uc patients undergoing proctocolectomy with creation of ileoanal j-pouch anastomosis.

Eligibility criteria:
inclusion criteria: * patients with ulcerative colitis and planned proctocolectomy with ileoanal j-pouch anastomosis surgery or patients who are to undergo subtotal colectomy. * age over 18 years. * written informed consent to take part in the study. * speaking ability in greek or english. * able to get tested fasted; exclusion criteria: * age under 18 years. * existence of pregnancy. * inability to breathe inside the indirect calorimetry mask for the time required for the measurement. * use of medications that may affect body metabolism will be evaluated individually (e.g. cortico-steroids etc.)

Keywords: ulcerative colitis energy requirements ileoanal anastomosis j-pouch
pilot study of curcumin formulation and ashwagandha extract in advanced osteosarcoma

Conditions: Osteosarcoma

Summary: curcumin as well as the ashwagandha extract are ingredients from traditional indian medicine and have been shown to be potent anti-cancer compounds in laboratory as well as animal studies. this study will test the safety and efficacy of a curcumin formulation and the ashwagandha extract in high grade relapsed or metastatic osteosarcoma where no other second line chemotherapy is being given. the pharmacokinetics will be studied along with response as measured on ct scans and pet scans as well as the quality of life and any toxicity.

eligibility criteria 1. osteosarcoma which has relapsed after treatment and for which no second line chemotherapy is planned and in which disease is not amenable to surgery. 2. patient should be able to follow-up 3 monthly for clinical and imaging assessment as well as biochemical tests

Eligibility criteria:
inclusion criteria: * patients (between the ages of 8 to 65 years) with histologically proven high grade osteosarcoma of the extremity and relapsed disease after primary line of treatment who are unsuitable or refuse secondary chemotherapy. * patients with advanced disease unable or unwilling to take primary conventional treatment * patients with early or non-metastatic disease who are unable or unwilling to take the standard chemotherapy. * adequate hepatic function defined by total bilirubin not more than 1.5 times the upper limit of normal (uln) and sgot and sgpt not more than 2.5 times the (uln) * adequate renal function defined by the creatinine clearance greater than 50 ml/min, calculated by cockcroft-gault formula exclusion criteria: * patients who are suitable for second line chemotherapy and can afford it * age less than 8 years or greater than 65 years * pregnant or lactating women * patients who are unable or unwilling to provide blood samples for the drug assays. * low grade osteosarcoma * patient requiring treatment with cyp3a4 inducers or inhibitors (patients on treatment for epilepsy or tuberculosis) * participation in any investigational drug study within 28 days prior to study treatment.

Keywords: curcumin ashwagandha osteosarcoma pharmacokinetics of curcumin and ashwagandha formulation response